SUN bioscience
Lausanne
About SUN bioscience
SUN bioscience is enabling personalized medicine through patient-specific organoids cultured on SUN’s proprietary high-throughput 3D microwell platform. Organoids are self-organizing 3D miniature tissues with organ-mimicking functions that are grown from stem cells. They are powerful human in vitro models for assessing pharmaceutical efficacy and toxicity early on in drug development. The SUN technology is solving the problems that organoid culture today cannot be scaled and automated. This will introduce a new area of drug discovery where we can understand drug performance outside of an animal or a human being.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $755.7K
- Funding stage: Seed
- Last round: Debt Financing (May 2021)
- Website: sunbioscience.ch
- Phone: +41216931615
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/sun-bioscience-117837 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.